3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Motor Activity
19
Polycystic Ovary Syndrome
10
Prostatic Neoplasms
7
Breast Neoplasms
6
Neoplasms
5
Colorectal Neoplasms
4
Insulin Resistance
3
Lung Neoplasms
2
Fatigue
2
Esophageal Neoplasms
2
Cardiotoxicity
2
Stomach Neoplasms
1
Rectal Neoplasms
1
Primary Dysautonomias
1
Pediatric Brain Tumor
1
Ovarian Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Lymphoma, Follicular
1
Lupus Erythematosus, Systemic
1
Inflammation
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Disease
1
Diabetes Mellitus, Type 1
1
Chemotherapy-Related Cognitive Impairment
1
Cardiovascular Diseases
1
Carcinoma, Hepatocellular
1
Cachexia
1
Interventions
Adalimumab
2
Vitamin D
1
Syringes
1
Sodium Chloride
1
Lysine Acetyltransferase 5
1
Injections
1
Holistic Health
1
High-Intensity Interval Training
1
Fish Oils
1
Fatty Acids, Omega-3
1
Exercise
1
Eicosapentaenoic Acid
1
Docosahexaenoic Acids
1
Cholecalciferol
1
Calcitriol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase NA
×
Arthritis, Rheumatoid
×
High-Intensity Interval Training
×
Clear all
NCT05215509
2024-02-02
RABEX
Rigshospitalet, Denmark
Phase NA
Completed
69 enrolled